RU2005140664A - Просматривающий мутагенез - Google Patents
Просматривающий мутагенез Download PDFInfo
- Publication number
- RU2005140664A RU2005140664A RU2005140664/13A RU2005140664A RU2005140664A RU 2005140664 A RU2005140664 A RU 2005140664A RU 2005140664/13 A RU2005140664/13 A RU 2005140664/13A RU 2005140664 A RU2005140664 A RU 2005140664A RU 2005140664 A RU2005140664 A RU 2005140664A
- Authority
- RU
- Russia
- Prior art keywords
- library
- polypeptide
- amino acid
- polynucleotides
- region
- Prior art date
Links
- 238000002703 mutagenesis Methods 0.000 title claims 2
- 231100000350 mutagenesis Toxicity 0.000 title claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 43
- 102000040430 polynucleotide Human genes 0.000 claims 43
- 239000002157 polynucleotide Substances 0.000 claims 43
- 229920001184 polypeptide Polymers 0.000 claims 43
- 108090000765 processed proteins & peptides Proteins 0.000 claims 43
- 102000004196 processed proteins & peptides Human genes 0.000 claims 43
- 238000000034 method Methods 0.000 claims 41
- 125000000539 amino acid group Chemical group 0.000 claims 19
- 108020004705 Codon Proteins 0.000 claims 16
- 239000012634 fragment Substances 0.000 claims 12
- 150000001413 amino acids Chemical class 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 230000015572 biosynthetic process Effects 0.000 claims 5
- 238000003786 synthesis reaction Methods 0.000 claims 5
- 239000012636 effector Substances 0.000 claims 4
- 239000000758 substrate Substances 0.000 claims 4
- 230000003197 catalytic effect Effects 0.000 claims 3
- 238000012216 screening Methods 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 101100495352 Candida albicans CDR4 gene Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 238000002819 bacterial display Methods 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 238000002823 phage display Methods 0.000 claims 2
- 238000002818 protein evolution Methods 0.000 claims 2
- 210000003705 ribosome Anatomy 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 108010032595 Antibody Binding Sites Proteins 0.000 claims 1
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 229940125532 enzyme inhibitor Drugs 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000003752 polymerase chain reaction Methods 0.000 claims 1
- 210000002729 polyribosome Anatomy 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 238000002702 ribosome display Methods 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48328203P | 2003-06-27 | 2003-06-27 | |
| US60/483,282 | 2003-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005140664A true RU2005140664A (ru) | 2007-08-27 |
Family
ID=33563915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005140664/13A RU2005140664A (ru) | 2003-06-27 | 2004-06-25 | Просматривающий мутагенез |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20050136428A1 (enExample) |
| EP (1) | EP1660655B1 (enExample) |
| JP (2) | JP4791960B2 (enExample) |
| KR (1) | KR20060034650A (enExample) |
| CN (1) | CN1836041A (enExample) |
| AU (1) | AU2004254352A1 (enExample) |
| BR (1) | BRPI0412007A (enExample) |
| CA (1) | CA2542192C (enExample) |
| ES (1) | ES2609102T3 (enExample) |
| IL (1) | IL172736A0 (enExample) |
| NO (1) | NO20060108L (enExample) |
| RU (1) | RU2005140664A (enExample) |
| WO (1) | WO2005003345A2 (enExample) |
| ZA (1) | ZA200510460B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2748231C2 (ru) * | 2016-01-08 | 2021-05-21 | Момотаро-Джин Инк. | Комбинированная терапия с использованием гена reic/dkk-3 и ингибитора контрольной точки иммунного ответа |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7329725B1 (en) * | 2003-10-29 | 2008-02-12 | Nastech Pharmaceutical Company Inc. | Phage displayed Trp cage ligands |
| WO2006014498A2 (en) | 2004-07-06 | 2006-02-09 | Bioren, Inc. | Universal antibody libraries |
| BRPI0511448A (pt) * | 2004-07-06 | 2007-12-26 | Bioren Inc | anticorpos anti-tnf-alfa de alta afinidade, método para a geração dos mesmos e biblioteca de seqüências |
| US9012369B2 (en) | 2004-07-06 | 2015-04-21 | Pfizer Inc. | Look-through mutagenesis for developing altered polypeptides with enhanced properties |
| WO2006094234A1 (en) * | 2005-03-03 | 2006-09-08 | Xencor, Inc. | Methods for the design of libraries of protein variants |
| US20080207467A1 (en) * | 2005-03-03 | 2008-08-28 | Xencor, Inc. | Methods for the design of libraries of protein variants |
| EP1877441A2 (en) * | 2005-04-26 | 2008-01-16 | Bioren, Inc. | Method of producing human igg antibodies with enhanced effector functions |
| WO2007019620A1 (en) * | 2005-08-15 | 2007-02-22 | Arana Therapeutics Limited | Engineered antibodies with new world primate framework regions |
| ES2402576T3 (es) * | 2005-11-14 | 2013-05-06 | Bioren, Inc. | Ultrahumanización de anticuerpos por generación y selección de bibliotecas cohorte y blast de cdr maduras previstas |
| US20110129414A1 (en) * | 2005-11-15 | 2011-06-02 | Balyasnikova Irina V | Single Chain Fragment of Monoclonal Antibody 9B9 and Uses Thereof |
| JP2009519983A (ja) | 2005-12-20 | 2009-05-21 | アラーナ・テラピューティクス・リミテッド | 部分的な新世界ザル結合領域を有するキメラ抗体 |
| EA017417B1 (ru) | 2006-02-01 | 2012-12-28 | Сефалон Астралия Пти Лтд. | КОНСТРУКТ ОДНОДОМЕННОГО АНТИТЕЛА, КОТОРЫЙ СВЯЗЫВАЕТСЯ С ЧЕЛОВЕЧЕСКИМ TNF-α, И ЕГО ПРИМЕНЕНИЕ |
| US7704953B2 (en) * | 2006-02-17 | 2010-04-27 | Mdrna, Inc. | Phage displayed cell binding peptides |
| WO2007112054A2 (en) * | 2006-03-23 | 2007-10-04 | Sea Lane Biotechnologies, Llc | Facilitation of translocation of molecules through the gastrointestinal tract |
| WO2007134327A2 (en) | 2006-05-15 | 2007-11-22 | Sea Lane Biotechnologies, Llc. | Neutralizing antibodies to influenza viruses |
| WO2007136840A2 (en) * | 2006-05-20 | 2007-11-29 | Codon Devices, Inc. | Nucleic acid library design and assembly |
| EP2057191A1 (en) | 2006-08-18 | 2009-05-13 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| US8131480B2 (en) | 2006-10-02 | 2012-03-06 | Sea Lane Biotechnologies Llc | Construction of diverse synthetic peptide and polypeptide libraries |
| US20080287320A1 (en) * | 2006-10-04 | 2008-11-20 | Codon Devices | Libraries and their design and assembly |
| JP5594895B2 (ja) * | 2007-06-06 | 2014-09-24 | ダニスコ・ユーエス・インク、ジェネンコー・ディビジョン | タンパク質の能力の改良方法 |
| WO2009009045A2 (en) * | 2007-07-10 | 2009-01-15 | The Scripps Research Institute | Escape libraries of target polypeptides |
| US8680019B2 (en) * | 2007-08-10 | 2014-03-25 | Protelica, Inc. | Universal fibronectin Type III binding-domain libraries |
| US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| US20090176654A1 (en) * | 2007-08-10 | 2009-07-09 | Protelix, Inc. | Universal fibronectin type III binding-domain libraries |
| CN101970490A (zh) | 2007-11-27 | 2011-02-09 | 埃博灵克斯股份有限公司 | 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽 |
| EP2698380A1 (en) | 2008-03-28 | 2014-02-19 | Sea Lane Biotechnologies, LLC | Neutralizing molecules to viral antigens |
| EP2131245A3 (en) * | 2008-06-02 | 2012-08-01 | ASML Netherlands BV | Lithographic apparatus and its focus determination method |
| WO2010115995A2 (en) | 2009-04-10 | 2010-10-14 | Ablynx Nv | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders |
| EP2417163B1 (en) | 2009-04-10 | 2019-02-27 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders |
| MX340541B (es) | 2009-06-05 | 2016-07-13 | Alblynx Nv | Secuencias de aminoacidos mejoradas dirigidas contra virus sincitial respiratorio humano y polipeptidos que comprenden las mismas para la prevencion y/o tratamiento de infecciones del tracto respiratorio. |
| CN102625848A (zh) * | 2009-07-17 | 2012-08-01 | 生物蛋白有限公司 | 在生产宿主中同时整合抗体/蛋白的性能和表达的筛选和演化的方法 |
| GB0914691D0 (en) * | 2009-08-21 | 2009-09-30 | Lonza Biologics Plc | Immunoglobulin variants |
| ES2860453T3 (es) | 2009-10-30 | 2021-10-05 | Novartis Ag | Bibliotecas universales del dominio de unión del lado inferior de la fibronectina de tipo III |
| US9644022B2 (en) | 2009-11-30 | 2017-05-09 | Ablynx N.V. | Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
| AU2011283646B2 (en) | 2010-07-30 | 2015-07-09 | Novartis Ag | Fibronectin cradle molecules and libraries thereof |
| US9753040B2 (en) | 2010-12-01 | 2017-09-05 | Mitsubishi Tanabe Pharma Corporation | Polynucleotide construct capable of displaying fab in a cell-free translation system, and method for manufacturing and screening fab using same |
| WO2013041722A1 (en) | 2011-09-23 | 2013-03-28 | Ablynx Nv | Prolonged inhibition of interleukin-6 mediated signaling |
| JP6415987B2 (ja) | 2012-03-02 | 2018-10-31 | アブリンクス エン．ヴェー． | シュードモナス・エルギノーサのＰｃｒＶに結合する単一可変ドメイン抗体 |
| WO2013158217A1 (en) * | 2012-04-20 | 2013-10-24 | Thomas Jefferson University | Engineered antibody for inhibition of fibrosis |
| DK2855674T4 (da) | 2012-05-25 | 2022-11-21 | Chr Hansen As | Chymosinvarianter med forbedrede mælkekoagulerende egenskaber |
| WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
| KR101600899B1 (ko) * | 2012-12-11 | 2016-03-09 | 주식회사 셀레믹스 | 초병렬적 핵산 합성법을 통한 dna 라이브러리의 동시 합성 방법 |
| US20140314741A1 (en) * | 2013-04-18 | 2014-10-23 | Developmen Center For Biotechnology | Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases |
| WO2015065987A1 (en) * | 2013-11-01 | 2015-05-07 | Ibc Pharmaceuticals, Inc. | Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease |
| CN104805507B (zh) * | 2014-01-29 | 2019-01-22 | 杭州康万达医药科技有限公司 | 噬菌体展示文库及其应用和制备方法 |
| BR112016017502B1 (pt) | 2014-02-26 | 2023-10-24 | Chr. Hansen A/S | Variantes de polipeptídeo de quimosina isoladas método para a produção das mesmas e método para a fabricação de um produto de alimentação humana ou animal |
| US10118967B2 (en) | 2014-10-21 | 2018-11-06 | Ablynx N.V. | Methods for treating rheumatoid arthritis by administering IL-6 receptor antibodies |
| CN107849550B (zh) | 2015-06-22 | 2021-09-03 | 科.汉森有限公司 | 具有改善的性质的凝乳酶变体 |
| JP2018525996A (ja) | 2015-08-31 | 2018-09-13 | セーホーエル．ハンセン アクティーゼルスカブ | 改良された特性を有するキモシンの変異体 |
| CN109640677A (zh) | 2016-05-19 | 2019-04-16 | 科·汉森有限公司 | 具有改善的凝乳特性的凝乳酶的变体 |
| JP7395251B2 (ja) | 2016-05-19 | 2023-12-11 | セーホーエル．ハンセン アクティーゼルスカブ | 改善された凝乳特性を有するキモシン変異体 |
| CN117298260A (zh) * | 2016-09-02 | 2023-12-29 | 莱蒂恩技术公司 | 用DuoCAR治疗癌症的组合物和方法 |
| MX2020006297A (es) | 2017-12-15 | 2020-12-07 | Aleta Biotherapeutics Inc | Variantes de cd19. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0527809B1 (en) * | 1990-04-05 | 1995-08-16 | CREA, Roberto | Walk-through mutagenesis |
| WO1995023813A1 (en) * | 1994-03-04 | 1995-09-08 | Merck & Co., Inc. | In vitro antibody affinity maturation using alanine scanning mutagenesis |
| US20030180714A1 (en) * | 1999-12-15 | 2003-09-25 | Genentech, Inc. | Shotgun scanning |
-
2004
- 2004-06-25 KR KR1020057025136A patent/KR20060034650A/ko not_active Withdrawn
- 2004-06-25 CA CA2542192A patent/CA2542192C/en not_active Expired - Lifetime
- 2004-06-25 CN CNA2004800229706A patent/CN1836041A/zh active Pending
- 2004-06-25 AU AU2004254352A patent/AU2004254352A1/en not_active Abandoned
- 2004-06-25 ES ES04756045.3T patent/ES2609102T3/es not_active Expired - Lifetime
- 2004-06-25 BR BRPI0412007-8A patent/BRPI0412007A/pt not_active IP Right Cessation
- 2004-06-25 EP EP04756045.3A patent/EP1660655B1/en not_active Expired - Lifetime
- 2004-06-25 US US10/877,467 patent/US20050136428A1/en not_active Abandoned
- 2004-06-25 RU RU2005140664/13A patent/RU2005140664A/ru not_active Application Discontinuation
- 2004-06-25 JP JP2006517625A patent/JP4791960B2/ja not_active Expired - Lifetime
- 2004-06-25 WO PCT/US2004/020306 patent/WO2005003345A2/en not_active Ceased
-
2005
- 2005-12-21 IL IL172736A patent/IL172736A0/en unknown
- 2005-12-22 ZA ZA200510460A patent/ZA200510460B/xx unknown
-
2006
- 2006-01-06 NO NO20060108A patent/NO20060108L/no not_active Application Discontinuation
-
2011
- 2011-03-22 JP JP2011062697A patent/JP5358604B2/ja not_active Expired - Lifetime
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2748231C2 (ru) * | 2016-01-08 | 2021-05-21 | Момотаро-Джин Инк. | Комбинированная терапия с использованием гена reic/dkk-3 и ингибитора контрольной точки иммунного ответа |
| RU2767997C2 (ru) * | 2016-01-08 | 2022-03-22 | Момотаро-Джин Инк. | КОМБИНИРОВАННАЯ ТЕРАПИЯ С ИСПОЛЬЗОВАНИЕМ ГЕНА REIC/Dkk-3 И ИНГИБИТОРА КОНТРОЛЬНОЙ ТОЧКИ ИММУННОГО ОТВЕТА |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4791960B2 (ja) | 2011-10-12 |
| JP5358604B2 (ja) | 2013-12-04 |
| IL172736A0 (en) | 2006-04-10 |
| BRPI0412007A (pt) | 2006-08-15 |
| EP1660655B1 (en) | 2016-11-02 |
| EP1660655A2 (en) | 2006-05-31 |
| CN1836041A (zh) | 2006-09-20 |
| KR20060034650A (ko) | 2006-04-24 |
| CA2542192C (en) | 2013-05-28 |
| JP2007524390A (ja) | 2007-08-30 |
| AU2004254352A1 (en) | 2005-01-13 |
| ZA200510460B (en) | 2006-11-29 |
| WO2005003345A3 (en) | 2005-03-24 |
| NO20060108L (no) | 2006-03-24 |
| WO2005003345A2 (en) | 2005-01-13 |
| JP2011182794A (ja) | 2011-09-22 |
| ES2609102T3 (es) | 2017-04-18 |
| US20050136428A1 (en) | 2005-06-23 |
| CA2542192A1 (en) | 2005-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005140664A (ru) | Просматривающий мутагенез | |
| CA2572917A1 (en) | Look-through mutagenesis for developing altered polypeptides with enhanced properties | |
| JP2011182794A5 (enExample) | ||
| Chao et al. | A mammalian SRB protein associated with an RNA polymerase II holoenzyme | |
| Li et al. | Minimization of a polypeptide hormone | |
| Goldman et al. | Selection of phage displayed peptides for the detection of 2, 4, 6-trinitrotoluene in seawater | |
| US7223547B2 (en) | Polypeptides having a functional domain of interest and methods of identifying and using same | |
| CA2461571A1 (en) | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins | |
| WO2003099999A3 (en) | Generation and selection of protein library in silico | |
| Hsu et al. | Selective deamidation of recombinant human stem cell factor during in vitro aging: isolation and characterization of the aspartyl and isoaspartyl homodimers and heterodimers | |
| RU2016149596A (ru) | Новые полипептиды со специфическим связыванием и пути их применения | |
| US20090233812A1 (en) | Target recognizing binding agents | |
| Lee et al. | MacProMass: a computer program to correlate mass spectral data to peptide and protein structures | |
| Erdjument‐Bromage et al. | High‐Sensitivity sequencing of large proteins: Partial structure of the rapamycin‐fkbp12 target | |
| AU733650B2 (en) | Identification and isolation of novel polypeptides having WW domains and methods of using same | |
| CN106749527A (zh) | 氯噻啉抗体特异性结合的噬菌体展示多肽及其用途 | |
| US7091046B2 (en) | Multiplexed protein expression and activity assay | |
| Demarest et al. | Optimization of the antibody CH3 domain by residue frequency analysis of IgG sequences | |
| Deshaies et al. | Charting the protein complexome in yeast by mass spectrometry | |
| Lee et al. | Accurate MALDI-TOF/TOF Sequencing of One-Bead− One-Compound Peptide Libraries with Application to the Identification of Multiligand Protein Affinity Agents Using in Situ Click Chemistry Screening | |
| Jankowski et al. | Disordered clock protein interactions and charge blocks turn an hourglass into a persistent circadian oscillator | |
| Zhao et al. | A paradigm for drug discovery using a conformation from the crystal structure of a presentation scaffold | |
| WO2014152660A1 (en) | Engineered antibody scaffolds | |
| CN110256531A (zh) | 吡虫啉抗体特异性结合的噬菌体展示多肽及其用途 | |
| Li et al. | A rare monoclonal antibody discovery based on indirect competitive screening of a single hapten-specific rabbit antibody secreting cell |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20071009 |